Pipeline

Pipeline of best-in-class TCEs for Immune-Mediated Diseases (IMDs)

Note: AIHA, autoimmune hemolytic anemia; ITP, immune thrombocytopenia; BP, bullous pemphigoid; PV, pemphigus vulgaris; IIS, investigator-initiated study; ODD: Orphan Drug Designation by US FDA; TCE, T-cell engager; SjD, Sjögren’s disease; IIM, idiopathic inflammatory myopathies including dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, anti-synthetase syndrome